key: cord-0683839-tsdg39d7
authors: Unterluggauer, L.; Pospischil, I.; Krall, C.; Saluzzo, S.; Kimeswenger, S.; Karolyi, M.; Wenisch, C.; Lamprecht, B.; Guenova, E.; Winkler, S.; Viczenczova, C.; Bergthaler, A.; Weninger, W.; Hoetzenecker, W.; Stary, G.
title: Cutaneous manifestations of SARS-CoV-2 – a two-center, prospective, case-controlled study
date: 2021-03-23
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.03.064
sha: ca8a51584b42b161ea7aa957a0b035bac19bb50c
doc_id: 683839
cord_uid: tsdg39d7

nan

limitations, including lack of laboratory confirmed COVID-19 diagnosis, suboptimal study 40 design or absence of case controls. 41

Here we report the results of a prospective and controlled cohort study with a four-week 42 follow-up period, in which we investigated potential skin findings in 102 hospitalized SARS-43

CoV-2 positive patients and 41 age-and sex-matched, SARS-CoV-2 negative controls with 44 acute, non-primary skin infectious diseases. In the control group the most common infections 45 were viral respiratory infections (26.8%), bacterial pneumonia (24.4%), and urinary tract 46 infections (14.6%). 47

We observed newly occurring skin signs concomitant with the infection in 17 (16.6%) COVID-48 19 patients. Three major groups of cutaneous manifestations were discerned: livedo 49 reticularis (6/5.8%), splinter haemorrhages-like lesions (4/3.9%) and subcutaneous nodules 50 Livedo reticularis occurred within the first and splinter haemorrhages-like lesion within the 60 third week, respectively, after disease onset (Figure 2) . Asymptomatic subcutaneous 61

nodules without systemic symptoms occurred in two patients 7 weeks after the occurrence of 62 respiratory symptoms (Figure 2) . Both suffered from a severe course of disease including 63 negative for SARS-CoV-2 by quantitative PCR testing in both patients. Five months after 66 study inclusion the patients reported spontaneous partial regression of the nodules. 67

The relatively small sample size must be considered as a limitation of our study. Therefore, 68

we might have missed less frequent cutaneous manifestations and could not achieve during the early course of disease and subcutaneous nodules as a possible late 72 manifestation, no statistically significant difference was detected when compared to a control 73 group of patients with other acute infectious diseases. Therefore, our study suggests that 74 skin manifestations in COVID-19 are less specific than previously assumed and cannot be 75 

Vascular skin 90 symptoms in COVID-19: a french observational study

Characterization of acute acral skin lesions in nonhospitalized 93 patients: A case series of 132 patients during the COVID-19 outbreak

The 96 spectrum of COVID-19-associated dermatologic manifestations: An international registry of 97 716 patients from 31 countries

Classification of the cutaneous manifestations of 100

COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Cutaneous manifestations in COVID-19: a first perspective